Go Pro

Gilead Sciences (GILD) 10K Form and Latest SEC Filings 2026

Gilead Sciences logo
$138.36 +0.22 (+0.16%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$138.26 -0.11 (-0.08%)
As of 08/14/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Gilead Sciences SEC Filings & Recent Activity

Gilead Sciences (NASDAQ:GILD) has submitted 765+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Gilead Sciences's financial statements. The most recent filing was a Form 4 submitted on August 11, 2026.

Form 4
GILEAD SCIENCES, INC. Reports Ownership Change on Aug. 11, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Gilead Sciences Files Current Report on Aug. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Gilead Sciences Files Quarterly Report on May. 7, 2026

The 10-Q contains Gilead Sciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Gilead Sciences SEC Filing History

Browse Gilead Sciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/11/2026 3:51 PM
Cain Wettan Keeley M (2110603) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:04 PM
Gilead Sciences (882095) Filer
Form S-3ASR
08/04/2026 4:40 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/04/2026 3:03 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/03/2026 3:41 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/16/2026 5:08 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2026 3:54 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2026 3:10 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/15/2026 3:13 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/16/2026 4:53 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 5:02 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2026 3:30 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/11/2026 5:29 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 5:31 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 5:32 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 5:34 PM
Cain Wettan Keeley M (2110603) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 5:35 PM
Berger Dietmar (1739515) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2026 5:04 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 3:45 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2026 7:55 PM
ASSEMBLY BIOSCIENCES, INC. (1426800) Issuer
Gilead Sciences (882095) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 7:51 PM
ASSEMBLY BIOSCIENCES, INC. (1426800) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D/A
05/20/2026 3:15 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/18/2026 4:45 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 4:50 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 3:15 PM
Gilead Sciences (882095) Filer
Form 424B5
05/14/2026 4:11 PM
Gilead Sciences (882095) Subject
Form FWP
05/14/2026 7:46 AM
Gilead Sciences (882095) Filer
Form 424B5
05/08/2026 4:00 PM
Gilead Sciences (882095) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
05/07/2026 4:12 PM
Gilead Sciences (882095) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2026 4:13 PM
Gilead Sciences (882095) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/07/2026 3:03 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2026 3:31 PM
Gilead Sciences (882095) Issuer
Horning Sandra (1638709) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:36 PM
BARTON JACQUELINE K (1183680) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:19 PM
Gilead Sciences (882095) Issuer
Kramer Kelly A. (1629885) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:20 PM
Gilead Sciences (882095) Issuer
MANWANI HARISH (1527726) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:05 PM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 5:41 PM
Gilead Sciences (882095) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 4:53 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 8:13 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D/A
04/28/2026 7:53 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
04/28/2026 7:56 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
The end may be near for these iconic stocks (Ad)

Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel

Watch Marc Chaikin's free presentation and get his full buy-and-sell list today
04/17/2026 8:00 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
04/16/2026 5:40 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 5:41 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:12 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 3:08 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2026 3:34 PM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-T/A
03/30/2026 4:59 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 3:03 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2026 5:40 PM
Gilead Sciences (882095) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/17/2026 5:56 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 5:14 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:45 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:24 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 3:46 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 1:49 PM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-C
02/23/2026 5:46 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/23/2026 5:48 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SC TO-C
02/23/2026 5:51 AM
Arcellx, Inc. (1786205) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D
02/18/2026 4:11 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 4:31 PM
Gilead Sciences (882095) Reporting
Xilio Therapeutics, Inc. (1840233) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2026 6:26 PM
Cain Wettan Keeley M (2110603) Reporting
Gilead Sciences (882095) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/06/2026 3:22 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:49 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:51 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 5:46 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 12:23 PM
FMR LLC (315066) Filed by
Gilead Sciences (882095) Subject
Form SCHEDULE 13G
01/29/2026 4:23 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 6:29 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 3:03 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 3:32 PM
Gilead Sciences (882095) Subject
Telman Deborah H (1860008) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2026 3:26 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 3:01 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2026 5:10 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 5:18 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2026 3:01 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2026 3:02 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2026 4:56 PM
Berger Dietmar (1739515) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:23 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:31 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:12 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:04 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/15/2025 3:04 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 7:38 PM
Gilead Sciences (882095) Issuer
O'Day Daniel Patrick (1638643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 7:40 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 5:25 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 5:11 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:36 PM
Gilead Sciences (882095) Reporting
Xilio Therapeutics, Inc. (1840233) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 12:02 PM
Bluestone Jeffrey (1771814) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/28/2025 12:05 PM
Gilead Sciences (882095) Subject
O'Day Daniel Patrick (1638643) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2025 3:16 PM
Gilead Sciences (882095) Subject
Kramer Kelly A. (1629885) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)

Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel

Get the name and ticker of Louis Navellier's #1 AI stock free
11/19/2025 7:30 AM
Gilead Sciences (882095) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2025 6:00 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 5:51 PM
Gilead Sciences (882095) Issuer
Mercier Johanna (1782135) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2025 3:05 PM
Dickinson Andrew D (1310204) Reporting
Gilead Sciences (882095) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 3:06 PM
Gilead Sciences (882095) Subject
Mercier Johanna (1782135) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 6:36 PM
Gilead Sciences (882095) Issuer
Telman Deborah H (1860008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 4:07 PM
Gilead Sciences (882095) Subject
Wilfong Diane E. (1374988) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 3:44 PM
Gilead Sciences (882095) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
11/05/2025 4:19 PM
Arcus Biosciences, Inc. (1724521) Subject
Gilead Sciences (882095) Filed by
Form SCHEDULE 13D/A
(Data available from 1/1/2016 forward)

Gilead Sciences SEC Filings - Frequently Asked Questions

Gilead Sciences (GILD) has submitted 765+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Gilead Sciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Gilead Sciences's financial statements page.

The most recent filing was a Form 4 submitted on August 11, 2026. This was an insider ownership change filed by 4 - GILEAD SCIENCES, INC. (0000882095) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:GILD) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners